Spotlight News

Mar 20, 2019
Overcoming Challenges in the Diagnosis of Rare Childhood-onset Epilepsies
Lennox-Gastaut syndrome (LGS) and Dravet syndrome are two rare, childhood-onset epilepsy disorders that pose considerable challenges to patients, families and clinicians.
Feb 26, 2019
CBD manufacturing process builds patient trust
At Greenwich Biosciences, central to our commitment to serving patient needs is our ability to bring forward prescription cannabinoid medicines that are effective and consistent.
May 05, 2018
The science and research behind cannabinoids
Learn more about the science and research behind cannabinoids, in our Spotlight interview with Professor Ben Whalley, Director of Research, GW Pharmaceuticals plc.
Apr 25, 2018
Greenwich Clinical Program Reflects Dedication to Scientific Rigor, Unmet Patient Needs
Our NDA submission and FDA review represented the culmination of 10 years of extensive preclinical and clinical research studying CBD, a cannabis plant component that lacks euphoric properties. This research includes three Phase 3 clinical trials involving approximately 500 patients.

For investor inquiries and media, please contact:

Stephen Schultz
Vice President, Investor Relations

Tel: 917.280.2424 Direct
Fax: 760.795.2219


Christy Curran
Sam Brown Inc.

Tel: 615-414-8668